To The Moon

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026. Company is debt-free after repaying mortgage on facilities. TNX-102 SL fibromyalgia FDA PDUFA goal date is August 15, 2025. $10.1 million in net sales from migraine products in 2024. CHATHAM, N.J., Feb. 07, 2025 -- Tonix Pharmaceuticals Holding Corp. , a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, recently announced selected preliminary operating results for the year ended December 31, 2024, and certain preliminary financial condition information as of December 31, 2024. The above information is preliminary financial information for the year ended December 31, 2024 and subject to completion. The unaudited, estimated results for the year ended December 31, 2024 are preliminary and were prepared by the Company's management, based upon its estimates, a number of assumptions and current

CleanSpark Inc reported first-quarter financial results after the market close on Thursday. Here’s a rundown of the report.Q1 Earnings: CleanSpark reported first-quarter revenue of $162.3 million, bea